Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Non-Current Assets: 2023-2025

Historic Non-Current Assets for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $19.3 million.

  • Artiva Biotherapeutics' Non-Current Assets fell 74.23% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year decrease of 74.23%. This contributed to the annual value of $20.9 million for FY2024, which is 17.17% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Non-Current Assets of $19.3 million as of Q3 2025, which was down 4.86% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Non-Current Assets ranged from a high of $75.0 million in Q3 2024 and a low of $19.3 million during Q3 2025.
  • Over the past 3 years, Artiva Biotherapeutics' median Non-Current Assets value was $21.3 million (recorded in 2025), while the average stood at $29.8 million.
  • Data for Artiva Biotherapeutics' Non-Current Assets shows a maximum YoY tumbled of 74.23% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Non-Current Assets stood at $25.3 million in 2023, then fell by 17.17% to $20.9 million in 2024, then slumped by 74.23% to $19.3 million in 2025.
  • Its Non-Current Assets was $19.3 million in Q3 2025, compared to $20.3 million in Q2 2025 and $21.3 million in Q1 2025.